Research ArticleCLINICAL INVESTIGATIONS
A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (R)-11C-Verapamil and PET
Claudia C. Wagner, Martin Bauer, Rudolf Karch, Thomas Feurstein, Stephan Kopp, Peter Chiba, Kurt Kletter, Wolfgang Löscher, Markus Müller, Markus Zeitlinger and Oliver Langer
Journal of Nuclear Medicine December 2009, 50 (12) 1954-1961; DOI: https://doi.org/10.2967/jnumed.109.063289
Claudia C. Wagner
Martin Bauer
Rudolf Karch
Thomas Feurstein
Stephan Kopp
Peter Chiba
Kurt Kletter
Wolfgang Löscher
Markus Müller
Markus Zeitlinger
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 50, Issue 12
December 2009
A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (R)-11C-Verapamil and PET
Claudia C. Wagner, Martin Bauer, Rudolf Karch, Thomas Feurstein, Stephan Kopp, Peter Chiba, Kurt Kletter, Wolfgang Löscher, Markus Müller, Markus Zeitlinger, Oliver Langer
Journal of Nuclear Medicine Dec 2009, 50 (12) 1954-1961; DOI: 10.2967/jnumed.109.063289
A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (R)-11C-Verapamil and PET
Claudia C. Wagner, Martin Bauer, Rudolf Karch, Thomas Feurstein, Stephan Kopp, Peter Chiba, Kurt Kletter, Wolfgang Löscher, Markus Müller, Markus Zeitlinger, Oliver Langer
Journal of Nuclear Medicine Dec 2009, 50 (12) 1954-1961; DOI: 10.2967/jnumed.109.063289
Jump to section
Related Articles
Cited By...
- ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery
- Characterization of P-Glycoprotein Humanized Mice Generated by Chromosome Engineering Technology: Its Utility for Prediction of Drug Distribution to the Brain in Humans
- Clinical Applications of Simultaneous PET/MR Imaging Using (R)-[11C]-Verapamil with Cyclosporin A: Preliminary Results on a Surrogate Marker of Drug-Resistant Epilepsy
- Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein
- Increased Permeability-Glycoprotein Inhibition at the Human Blood-Brain Barrier Can Be Safely Achieved by Performing PET During Peak Plasma Concentrations of Tariquidar
- Role of (Drug) Transporters in Imaging in Health and Disease
- In Vivo Imaging as a Pharmacodynamic Marker
- Interaction of 11C-Tariquidar and 11C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood-Brain Barrier
- Retrospective Analysis of P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier in Humans
- Modeling Cyclosporine A Inhibition of the Distribution of a P-Glycoprotein PET Ligand, 11C-Verapamil, into the Maternal Brain and Fetal Liver of the Pregnant Nonhuman Primate: Impact of Tissue Blood Flow and Site of Inhibition
- Behavioral Effects and Central Nervous System Levels of the Broadly Available {kappa}-Agonist Hallucinogen Salvinorin A Are Affected by P-Glycoprotein Modulation In Vivo
- A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood-Brain Barrier